Authors
- Eleonora Proia*
- Alessio Ragno*
- Lorenzo Antonini*
- Manuela Sabatino*
- Milan Mladenovič*
- Roberto Capobianco
- Rino Ragno*
* External authors
Venue
- Journal of Computer-Aided Molecular Design
Date
- 2022
Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal
Eleonora Proia*
Alessio Ragno*
Lorenzo Antonini*
Manuela Sabatino*
Milan Mladenovič*
Rino Ragno*
* External authors
Journal of Computer-Aided Molecular Design
2022
Abstract
The main protease (Mpro) of SARS-Cov-2 is the essential enzyme for maturation of functional proteins implicated in viral replication and transcription. The peculiarity of its specific cleavage site joint with its high degree of conservation among all coronaviruses promote it as an attractive target to develop broad-spectrum inhibitors, with high selectivity and tolerable safety profile. Herein is reported a combination of three-dimensional quantitative structure–activity relationships (3-D QSAR) and comparative molecular binding energy (COMBINE) analysis to build robust and predictive ligand-based and structure-based statistical models, respectively. Models were trained on experimental binding poses of co-crystallized Mpro-inhibitors and validated on available literature data. By means of deep optimization both models’ goodness and robustness reached final statistical values of r2/q2 values of 0.97/0.79 and 0.93/0.79 for the 3-D QSAR and COMBINE approaches respectively, and an overall predictiveness values of 0.68 and 0.57 for the SDEPPRED and AAEP metrics after application to a test set of 60 compounds covered by the training set applicability domain. Despite the different nature (ligand-based and structure-based) of the employed methods, their outcome fully converged. Furthermore, joint ligand- and structure-based structure–activity relationships were found in good agreement with nirmatrelvir chemical features properties, a novel oral Mpro-inhibitor that has recently received U.S. FDA emergency use authorization (EUA) for the oral treatment of mild-to-moderate COVID-19 infected patients. The obtained results will guide future rational design and/or virtual screening campaigns with the aim of discovering new potential anti-coronavirus lead candidates, minimizing both time and financial resources. Moreover, as most of calculation were performed through the well-established web portal 3d-qsar.com the results confirm the portal as a useful tool for drug design.
Related Publications
Recent advances in protein-protein interaction (PPI) research have harnessed the power of artificialintelligence (AI) to enhance our understanding of protein behaviour. These approaches have becomeindispensable tools in the field of biology and medicine, enabling scientists …
Non-markovian Reinforcement Learning (RL) tasks arevery hard to solve, because agents must consider the entire history ofstate-action pairs to act rationally in the environment. Most works usesymbolic formalisms (as Linear Temporal Logic or automata) to specify the temporall…
Explainable AI seeks to unveil the intricacies of black box models through post-hoc strategies or self-interpretable models. In this paper, we tackle the problem of building layers that are intrinsically explainable through logical rules. In particular, we address current st…
JOIN US
Shape the Future of AI with Sony AI
We want to hear from those of you who have a strong desire
to shape the future of AI.